ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Core Viewpoint - ALX Oncology Holdings Inc. plans to report its fourth quarter and full year 2024 financial results on March 6th, 2025, before market open [1]. Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing therapies that enhance the immune system to treat cancer and improve patient survival [3]. - The company's lead therapeutic candidate, evorpacept, is being evaluated in multiple ongoing clinical trials across various cancer indications, indicating its potential as a cornerstone therapy in immuno-oncology [3].